Medical treatment modalities for lower urinary tract symptoms: What are the relevant differences in randomised controlled trials?

European Urology

Volumn 38, Issue SUPPL. 1, 2000, Pages 18-24

  Zimmern, Philippe ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Drug therapy; Effec tiveness; Efficacy; Finasteride; LUTS; Phytotherapy; Randomised controlled trials; Tolerability; 1 Adrenoceptor

Indexed keywords

ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; FINASTERIDE; PLACEBO; SABAL EXTRACT; TERAZOSIN;

AGED; ASTHENIA; CLINICAL PRACTICE; CLINICAL TRIAL; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG EFFICACY; DRUG TOLERANCE; FEMALE; GYNECOMASTIA; HEALTH CARE; HUMAN; IMPOTENCE; INCIDENCE; ITALY; MAJOR CLINICAL STUDY; MALE; ORTHOSTATIC HYPOTENSION; PHYTOTHERAPY; PREVALENCE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RETROGRADE EJACULATION; SABAL; SYNCOPE; URETHRA DISEASE; URINE FLOW RATE; URINE RETENTION; VERTIGO;

EID: 0033667529     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1159/000052398     Document Type: Conference Paper

References (30)

1. High prevalence of benign prostatic hypertrophy in the community
2. The prevalence of prostatism: A population-based survey of urinary symptoms
3. BPH disease management, introduction and concluding remarks
4. Who should be treated and how? Evidence-based medicine in symptomatic BPH
5. The efficacy of terazosin, finasteride or both in benign prostatic hyperplasia
6. Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia
7. Results of the PREDICT (Prospective Eu-ropean doxazosin and combination therapy) trial
8. The effect of finasteride in men with benign prostatic hyperplasia
9. Finasteride (MK-906) in the treatment of benign prostatic hyper-plasia
10. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis of randomized clinical trials
11. The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response
12. Impact of prostate size on response to medical therapy for benign prostatic hyperplasia (BPH): Results of the PREDICT trial
13. Comparison of phytotherapy (Per-mixon®) with finasteride in the treatment of benign prostatic hyperplasia: A randomized international study of 1,098 patients
14. Phytotherapy for treatment of benign prostatic hyperplasia: Case not proven
15. Comparative effects of alfuzosin versus Serenoa repens in the treatment of symptomatic benign prostatic hyperplasia
16. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: Results of a 2-year randomized controlled trial (the PROSPECT Study)
17. The safety of finasteride used in benign prostatic hypertrophy: A non-interventional cohort study in 14772 patients
18. 1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction
19. Safety profile of 3 months' therapy with alfuzosin in 13389 patients suffering from benign prostatic hypertrophy
20. Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic BPH)
21. 1-adrenoceptor antagonist in benign prostatic hyperplasia: Studies on tamsulosin in a fixed dose and terazosin in increasing doses
22. Clinical comparison of selective and non-selective alpha1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: Studies on tamsulosin and terazosin in Chinese patients
23. A double-blind comparison of terazosin and tamsulosin on their differential effects on ambulatory blood pressure and nocturnal orthostatic stress testing
24. Natural history of prostatism: Risk factors for acute urinary retention
25. The natural history of patients with benign prostatic hyperplasia as diagnosed by North American urologists
26. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia
27. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia
28. Urinary retention in patients with BPH treated with finasteride or placebo over 4 years